Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Xilio Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 37 | 1 | 24 | −12 |
| SharesConverted for a 1-for-14 split | 2.84M | 89.7K | 2.62M | −128.5K (−4.7%) |
| Value | $25.4M | $803.6K | $22.0M | −$2.60M (−10.6%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 123,660 | $1.04M | 0.00% |
| Caligan Partners LP | 112,128 | $943.0K | 0.07% |
| Vanguard Fiduciary Trust Co | 28,475 | $239.5K | 0.00% |
| CWM, LLC | 4,206 | $35.4K | 0.00% |
| JPMorgan Chase & Co | 240 | $1.98K | 0.00% |
| Vanguard Global Advisers, LLC | 210 | $1.77K | 0.00% |
| Royal Bank of Canada | 91 | $1.00K | 0.00% |
Sold out (19)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Point72 Asset Management, L.P. | 4,000,000 | $2.56M |
| StemPoint Capital LP | 2,030,028 | $1.30M |
| Empery Asset Management, LP | 1,183,040 | $757.4K |
| Citadel Advisors LLC | 436,216 | $279.3K |
| Northern Trust Corp | 66,609 | $42.6K |
| Two Sigma Investments, LP | 62,032 | $39.7K |
| Bridgeway Capital Management, LLC | 56,081 | $35.9K |
| Jane Street Group, LLC | 42,080 | $26.9K |
| HRT Financial LP | 31,886 | $20.0K |
| Mariner, LLC | 25,000 | $16.0K |
| LPL Financial LLC | 21,000 | $13.4K |
| Raymond James Financial Inc | 18,761 | $12.0K |
| XTX Topco Ltd | 17,304 | $11.1K |
| Dunhill Financial, LLC | 10,274 | $6.58K |
| Investors Asset Management of Georgia Inc | 10,000 | $6.40K |
| Pinnacle Financial Group, LLC | 10,000 | $6.40K |
| BlackRock, Inc. | 2,037 | $1.30K |
| Private Wealth Management Group, LLC | 310 | $199 |
| Bank of America Corp | 261 | $167 |
Not filed for Q1 2026 yet (1)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 1,255,692 | $803.6K |